Zoetis (ZTS) Other Accumulated Expenses (2013 - 2026)
Zoetis (ZTS) posted quarterly Other Accumulated Expenses of $121.0 million for Q1 2026, down 84.33% year-over-year from $772.0 million in Q1 2025, and down 85.61% quarter-over-quarter from $841.0 million in Q4 2025.
Zoetis (ZTS) Other Accumulated Expenses (2013 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Other Accumulated Expenses for 14 consecutive years, with $121.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 84.33% year-over-year to $121.0 million; the TTM figure through Mar 2026 stood at $121.0 million (down 84.33% YoY), while the FY2025 annual figure was $841.0 million, up 572.8% from the prior year.
- Other Accumulated Expenses fell to $121.0 million in Q1 2026 per ZTS's latest filing, from $841.0 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $841.0 million in Q4 2025 and bottomed at $89.0 million in Q1 2024.
- Historically, Other Accumulated Expenses has averaged $399.8 million across 5 years, with a median of $125.0 million in 2024.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses sank 87.3% — and 2025, when it surged 767.42%.
- Zoetis' Other Accumulated Expenses stood at $97.0 million in 2022, then increased by 5.15% to $102.0 million in 2023, then climbed by 22.55% to $125.0 million in 2024, then surged by 572.8% to $841.0 million in 2025, then tumbled by 85.61% to $121.0 million in 2026.
- Business Quant data shows ZTS's Other Accumulated Expenses at $121.0 million in Q1 2026, $841.0 million in Q4 2025, and $99.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 856.00 Mn |
| Mar 31, 2026 | 121.00 Mn |
| Dec 31, 2025 | 841.00 Mn |
| Sep 30, 2025 | 99.00 Mn |
| Jun 30, 2025 | 770.00 Mn |
| Mar 31, 2025 | 772.00 Mn |
| Dec 31, 2024 | 125.00 Mn |
| Sep 30, 2024 | 115.00 Mn |
| Jun 30, 2024 | 704.00 Mn |
| Mar 31, 2024 | 89.00 Mn |
| Dec 31, 2023 | 102.00 Mn |
| Sep 30, 2023 | 97.00 Mn |
| Jun 30, 2023 | 689.00 Mn |
| Mar 31, 2023 | 701.00 Mn |
| Dec 31, 2022 | 97.00 Mn |
| Sep 30, 2022 | 679.00 Mn |
| Jun 30, 2022 | 696.00 Mn |
| Mar 31, 2022 | 99.00 Mn |
| Dec 31, 2021 | 67.00 Mn |
| Sep 30, 2021 | 618.00 Mn |